A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Novartis
Assiut University
Baylor College of Medicine
Centre Leon Berard
Novartis
American University of Beirut Medical Center
Obafemi Awolowo University
OHSU Knight Cancer Institute
Medical College of Wisconsin
University of Pisa
M.D. Anderson Cancer Center
Sir Mortimer B. Davis - Jewish General Hospital
Hikma Pharmaceuticals LLC
University of Liverpool
University of Jena
Ascentage Pharma Group Inc.
Poitiers University Hospital
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Australasian Leukaemia and Lymphoma Group
Novartis
OHSU Knight Cancer Institute
University of Auckland, New Zealand
Sumitomo Pharma America, Inc.
Pfizer
Medical College of Wisconsin
UNC Lineberger Comprehensive Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Institut Bergonié
Novartis
Novartis
Novartis
Pfizer
Mansoura University
Hikma Pharmaceuticals LLC
Novartis
Dana-Farber Cancer Institute
National Research Center for Hematology, Russia
Poitiers University Hospital
Fred Hutchinson Cancer Center
University of Milano Bicocca
University Hospital Freiburg
Novartis
Imperial College London